Navigation Links
ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer

Lung cancer, the header among all forms of cancer, is avenged now by the new proven effective ZD1839.

It has been shown that ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, has confirmed, durable responses and safety in patients with advanced non-small cell lung cancer (NSCLC) as monotherapy and in combination with standard chemotherapy agents after segmental scrutinization in two different studies.

Vincent Miller, MD, of Memorial Sloan-Kettering Cancer Center in New York and the principal investigator of the first study said, "It is hoped that our study will be a prelude to better outcomes for NSCLC patients in the near future." No novel toxicities were seen with ZD1839 treatment in combination with standard chemotherapy.

In a second study, which addressed intermittent dosing of ZD1839 in Japanese patients with advanced lung cancer, more than 20% of patients showed partial responses to ZD1839 between 1 and 11 months.

With such promising results, researchers are now working on whether this drug can be used for other forms of cancer as well.
'"/>




Page: 1

Related medicine news :

1. Study Proves That MMR Vaccine Is Not Connected To Autistic Babies
2. Pilot Study Proves Home Abortions ‘Safe’
3. Many Nonprescription Cough Medicines Proves Ineffective
4. Less Invasive By Pass Surgery Proves Economical In The Long Run
5. Epidural Mistakes Proves To Be Fatal Blunders
6. Combined Anti-Fever Drug Therapy Proves Unsafe for Childhood Fever
7. Drug Trial Proves Nightmare for British Indian Student
8. Naturopathic Care Proves Beneficial for TMD Pain
9. Medtronic Device Proves Effective in Parkinson’s Diseas
10. Large Community Spirometry Screening Proves Successful
11. Pregabalin Proves Durable Pain Relief Option for Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... Greenfield Advisors ... companies in the U.S. for the second year in a row. The Inc. 5000 ... past three years. , “To be on the list once is a great accomplishment, ...
(Date:8/16/2017)... ... August 16, 2017 , ... For the second year, ... student to educate the public on the impact of concussions. Brooke Mills, student ... National Concussion Awareness Day. , Brooke is working diligently is to raise awareness ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... of their recently launched community enrichment program. Partnering once again with Boys & ... Superstar competition to help find the area’s very own American Idol. With all ...
(Date:8/16/2017)... ... August 16, 2017 , ... LabRoots , the ... from around the world, is excited to announce Andrew Ly as the winner of ... pursuits, covering textbook costs. , Ly, who is in his third year at ...
(Date:8/16/2017)... ... August 16, 2017 , ... Melbourne’s reign as the world’s most liveable city ... (EIU) annual Liveability Index. , The Index surveys 140 of the world’s cities and ... Melbourne has consistently come in the top three of the index. So what is ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, a ... active in the biopharmaceutical, nutraceutical, and aquacultural feed ... of its lead drug candidates, AGR131.  This drug ... cytokine from the blood of patients suffering from ... inflammatory bowel disease. ...
(Date:8/2/2017)... 2017   Marshall County Hospital in Benton, Kentucky has ... of hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for "total room ... pathogens such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/1/2017)... , Aug. 1, 2017   CerSci Therapeutics , ... Dallas, Texas , has received notice from the ... Institutes of Health (NIH) that it has been awarded ... totaling over $650,000 in 2017 with an additional $1,000,000 ... Investigational New Drug application of their lead non-opioid drug ...
Breaking Medicine Technology: